Tag: Adamas Pharmaceuticals

News, Pricing, Regulations

Adamas Pharmaceuticals Announces Pricing of Follow-on Public Offering

February 25, 2021

Via: BioSpace

Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a company dedicated to developing and delivering medicines that make a meaningful difference to people affected by neurological diseases, today announced the pricing of its underwritten public offering of 12,500,000 shares of its common stock […]